Keywords
Drosperinone
17β-Estradiol
Menopause
Osteoporosis
How to Cite
Abstract
Introduction: The climacteric and menopause can alter the quality of life of women, producing sequelae due to the increased risk of osteoporosis (OP) and ischemic cardiovascular disease. Objective: To determine the bone mineral density (BMD) in postmenopausal women treated with 17β-estradiol/Drospirenone attending in the Menopause and Gynecology consultations at the Hospital "Dr. Pedro García Clara " in Ciudad Ojeda, Zulia State. Methods: A comparative research with a case-control, non-experimental, and transactional design, where was studied the bony mineral density (BMD) at both the lumbar spine and femoral neck in 60 postmenopausal women, divided into two matched groups according if received (cases) or not (controls), 17β-estradiol/Drosperinone as hormone replacement therapy (HRT). Results: It was found that women using this HRT had a very significant (p <0.001) both improved BMD as better scores on the indices T projections at lumbar spine and femoral neck when compared with those who don´t received hormonal treatment, which resulted in a lower prevalence of Osteoporosis (6.67% vs. 30.00%) and osteopenia (13.33% vs. 46.67%), having the non-users of hormone therapy a significant risk (p <0.05) of 6 times more likely to have some change in BMD. Conclusion: The use of 17β estradiol HRT in postmenopausal women represented a protective factor for developing Osteoporosis or Osteopenia.
References
Sennot L. La mujer de edad avanzada en las Américas. Problemas y posibilidades. En: Gómez, E., (Ed.) Género, mujer y salud en las Américas. Washington, DC: OPS; 2003. pp. 114-123.
Álvarez R; Martín E; Bordones M. Conocimiento y actitud sobre el climaterio en mujeres entre 40 y 50 años. Rev Obstet Ginecol Venez. 2008; 68 (1): 32- 40
Urdaneta J, Baabel N, Guerra M, Contreras A, Fernández M, Labarca L. Calidad de vida en posmenopáusicas tratadas con tibolona. Rev. Digit. Postgrado. 2017; 6(1): 11 – 27.
Makker A; Singh MM; Mishra G; Singh BP; Jain GK; Jadhav S. Relationship between bone turnover biomarkers, mandibular bone mineral density, and systemic skeletal bone mineral density in premenopausal and postmenopausal Indian women. Menopause, 2012; 19 (6): 642 - 649.
Medina A, Rosero O, Rueda PN, Sánchez F, Chalem M, González MA, et al. II Consenso Colombiano para el Manejo de la Osteoporosis Posmenopáusica. Rev Colomb Reumatol. 2018;25(3):184–210
Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, et al. Osteoporosis: A Review of Treatment Options. P T. 2018; 43 (2):92-104.
Anil G; Guglielmi G; Peh Wcg. Radiology of Osteoporosis. Radiol Clin N Am. 2010; 48: 497 – 518.
IOF. The Latin America Regional Audit. Epidemiología, costos e impacto de la osteoporosis en 2012.
González J; Guañabens N; Gómez C; del Río L; Muñoz M; Delgado M; et al. Guías de práctica clínica en la Osteoporosis posmenopáusica, glucocorticoidea y del varón. Rev Clín Esp. 2008; 208 (Supl. 1): 1 - 24.
Organización Mundial de la Salud. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. WHO Technical Report Series 843. Ginebra: WHO; 1994. p. 26.
Reynaga B; Zeni SN. Marcadores bioquímicos del remodelamiento óseo. Utilidad clínica. Acta Bioquím Clín Latinoam. 2009; 43 (2): 177 – 193.
Akkawi I, Zmerly H. Osteoporosis: Current Concepts. Joints 2018; 06(02): 122-127
Sioka C. Age at menarche, age at menopause and duration of fertility as risk factors for osteoporosis. Climacteric. 2010; 13 (1): 63 – 71.
Santen RJ, Craig-Allred D, Ardoin SP, Archer DF. Executive summary: Postmenopausal hormone therapy: an Endocrine Society Scientific Statement. J Clin Endocrinol Metab 2010; 95 (Suppl. 1): S1-S66.
Balderramo DC; Ramacciotti CF; Douthat WG. Factores de riesgo para osteoporosis primaria en mujeres de Córdoba, Argentina. Medicina (Buenos Aires). 2004; 64 (5): 400 – 406.
Horst W; Wawrzyniak A. The role of hormonal therapy in osteoporosis. Pol J Endocrinol. 2011; 62 (1): 61 – 64.
Castelo C; Cancelo MJ. Efectos de la terapia hormonal sustitutiva y tibolona sobre el hueso. Densidad mineral y riesgo de fractura. REVCOG. 2009; 14 (4): 136 - 144.
Sitruk-Ware R; Nath A. The use of newer progestins for contraception. Contraception. 2010; 82 (5): 410 - 417.
Foidart JM; Faustmann T. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen. Gynecol Endocrinol. 2007; 23 (12): 692 - 699.
Özdemir F; Demirbağ D; Türe M. Do Dietary Calcium Intake and Hormone Replacement Therapy Affect Bone Mineral Density in Women? Trakya Univ Tip Fak Derg. 2008; 25 (2): 105 – 109.
Anderson G; Limacher M. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative Randomized Controlled Trial. JAMA. 2004; 291(14): 1701 - 1712.
Navarro D; Nicolau O. Terapia hormonal y calidad del hueso. Rev Cubana Endocrinol. 2005; 16 (2) [Periódico en línea]. Disponible en: http://bvs.sld.cu/revistas/end/vol16_2_05/end03205.htm. Fecha de recuperación: 19 de Junio de 2012.
Lugones M. Osteoporosis en la menopausia. Prevención y estrategias terapéuticas actuales. Rev Cubana Obstet Ginecol. 2001; 27 (3): 199 – 204.
Vesco KK; Marshall LM; Nelson HD; Humphrey L; Rizzo J; Pedula KL; et al. Surgical menopause and nonvertebral fracture risk among older US women. Menopause. 2012; 19 (5): 510 - 516.
Simon LS. Osteoporosis. Rheum Dis Clin N Am. 2007; 33: 149 176.
Masoni A; Morosano M; Florencia M; Pezzotto SM; Sanchez A. Factores de riesgo para osteoporosis y fracturas de cadera. Análisis multivariado. Medicina. 2007; 67 (5): 423 – 428.
Vázquez M; López A; Isasi C; Aguado P. Fractura osteoporótica: valoración del riesgo en la práctica clínica. Med Clin (Barc). 2007; 129 (11): 418 – 423.
González LA; Vásquez GM; Molina JF. Epidemiología de la osteoporosis. Rev Colomb Reumatol. 2009; 16 (1): 61 – 75.
Compston J. Osteoporosis: Social and Economic Impact. Radiol Clin N Am. 2010; 48: 477 – 482.
Riera G. Epidemiology of osteoporosis in Latin America 2008. Salud pública Méx. 2009; 51 (1): s52 - s55.
Pineda LM. Osteoporosis en el climaterio y menopausia. Tesis de especialización en Obstetricia y Ginecología. Facultad de Medicina, Universidad del Zulia. 2008 [Tesis en línea] Disponible en: http://tesis.luz.edu.ve/tde_busca/arquivo.php?codArquivo=2928. Fecha de recuperación: 10 de Mayo de 2019.
Couto D; Nápoles D; Deulofeu I. Osteoporosis posmenopausia según densitometría ósea. MEDISAN. 2011; 15 (12): 1765 – 1774.
Terán J; Teppa A; Febres C. Actualidad en el diagnóstico de la osteoporosis posmenopáusica. Rev Obstet Ginecol Venez. 2007; 67 (2): 115 – 125.
López JE; López-SalazarJE; López Y; Fasanella H. Osteoporosis: alimentación, calcio, vitamina D y ejercicio. Gac Méd Caracas. 2007; 115 (4): 286 – 291
Fernández DG; Mora C; Reyes E; Londoño JD; Santos P; Valle R. Tratamiento farmacológico de la osteoporosis postmenopáusica. Rev Colomb Reumatol. 2010; 17 (2): 96 – 110.
Arana E; Gutiérrez I; Ecenarro A; Asua J. Prevalencia de ciertos hábitos determinantes de Osteoporosis en mujeres postmenopáusicas del País Vasco en 2003. Rev Esp Salud Pública. 2007; 81 (6): 647 – 656.
Hermoso MT. Clasificación de la osteoporosis. Factores de riesgo. Clínica y diagnóstico diferencial. An Sist. Sanit. Navar. 2003; 26 (3): 29 - 52.
Landa MC. Papel de la terapia hormonal sustitutiva, en la prevención y tratamiento de la osteoporosis menopáusica. Anales Sis San Navarra. 2003; 26 (Suppl. 3): 99 – 105.
Buttros DAB; Nahas-Neto J; Nahas EAP; Cangussu LM; Barral ABCR; Kawakami MS. Fatores de risco para osteoporose em mulheres na pós-menopausa do sudeste brasileiro. Rev Bras Ginecol Obstet. 2011; 33 (6): 295 – 302.
Francucci CM. Effect of natural early menopause on bone mineral density. Maturitas. 2008; 59 (4): 323 – 328.
Gallagher JC. Effect of early menopause on bone mineral density and fractures. Menopause. 2007; 14 (3): 567 - 571.
Pinheiro MM. Clinical risk factors for osteoporotic fractures in Brazilian women and men: the Brazilian Osteoporosis Study (BRAZOS). Osteoporos Int. 2009; 20 (3): 399 – 408.
Urdaneta J; Cepeda M; Guerra M; Baabel N; Contreras A. Calidad de vida en mujeres menopausicas con y sin terapia de reemplazo hormonal. Rev Chil Obstet Ginecol. 2010; 75 (1): 17 – 34.
Özkaya E; Cakir E; Okuyan E; Cakir C; Ustün G; Küçüközkan T. Comparison of the effects of surgical and natural menopause on carotid intima media thickness, osteoporosis, and homocysteine levels. Menopause. 2011; 18 (1): 73 – 76.
Guerra JR, Urdaneta JR, Villalobos N, Contreras A, Garcia J, Baabel N, et al. Factores de riesgo para alteraciones de la densidad mineral ósea en mujeres posmenopáusicas Rev Chil Obstet Ginecol 2015; 80(5): 385 - 393
Kritz D; von Mühlen DG; Barrett E. Hysterectomy and oophorectomy are unrelated to bone loss in older women. Maturitas. 2004; 47 (1): 61 - 69.
López J. Efectividad del tratamiento para la osteoporosis en la densidad mineral ósea de pacientes menopáusicas. Tesis de especialización en Medicina Interna. Facultad de Medicina, Universidad del Zulia. 2005. [Tesis en línea] Disponible en: http://tesis.luz.edu.ve/tde_busca/arquivo.php?codArquivo=1976. Fecha de recuperación: 10 de Mayo de 2012.
Pasco JA; Kotowicz MA; Henry MJ; Sanders KM; Seeman E; Nicholson GC. Hormone therapy and risk of non-vertebral fracture: Geelong Osteoporosis Study. Osteoporos Int. 2004; 15 (6): 434 - 438
Arrenbrecht S; Boermans AJ. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial. Osteoporos Int. 2002; 13 (2): 176 - 83.
Hadji P, Colli E, Regidor PA. Bone health in estrogen-free contraception. Osteoporos Int 2019; 30: 2391–2400
Römer T, Bitzer J, Egarter C, Hadji P, Kiechle M, Kramer H, et al. Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone. Geburtshilfe Frauenheilkd 2021; 81 (09): 1021-1030.
Ciebiera M, Włodarczyk M, Słabuszewska-Jóźwiak A, Ciebiera M, Nowicka G, Jakiel G. Vitamin D serum levels in women using contraception containing drospirenone - a preliminary study. Arch Med Sci. 2019; 15 (2):554-557
Gasparyan S, Drosova L, Khripunova A, Karpov S, Vishlova I. The effect of low-dose drospirenone and 17β-estradiol for correction of the manifestations of climacteric syndrome in postmenopausal women. European science review. 2017; (3-4)
Warming L, Ravn P, Nielsen T, Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis, Climacteric, 2004; 7 (1): 103 - 111.
Christiansen C. Effects of drospirenone/estrogen combinations on bone metabolism, Climacteric. 2005; 8 (Sup. 3): 35 – 41.
Archer DF. Drospirenone and estradiol: a new option for the postmenopausal woman, Climacteric. 2007; 10 (Sup. 1): 3 – 10.
Gambacciani M, Cagnacci A, Lello S. Hormone replacement therapy and prevention of chronic conditions. Climacteric. 2019; 22 (3): 303 – 306.
Britto R; Araújo L; Barbosa I; Silva L; Rocha S; Valente AP. Hormonal therapy with estradiol and testosterone implants: bone protection? Gynecol Endocrinol. 2011; 27 (2): 96 - 100.
Yates J; Barrett E; Barlas S; Chen YT; Miller PD; Siris ES. Rapid loss of hip fracture protection after estrogen cessation: Evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol. 2004; 103 (3): 440 – 446.
Wittich AC. Osteoporosis y terapia de reemplazo hormonal. Rev Argent Endocrinol Metab. 2004; 41: 24-25.
Lewiecki EM. Prevention and treatment of postmenopausal Osteoporosis. Obstet Gynecol Clin N Am. 2008; 35: 301 – 315.
Moreno MC; Centelles F; Jovell E. Indicación de densitometría ósea en mujeres mayores de 40 años. Aten Primaria. 2005; 35 (5): 253 – 257.
Suby JA; Estévez JM; Vazquez JA; Villa DV. Densidad mineral ósea de antebrazo en una muestra de la población femenina de Mar del Plata. Rev Argent Endocrinol Metab. 2005; 42 (1): 20 - 27.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2022 Nasser Baabel-Romero, José Ramón Urdaneta, Nasser Baabel-Zambrano, Richard Mejia, Alegría Levy